Lantheus Holdings (LNTH) Hisse Özeti
Lantheus Holdings, Inc. dünya çapında kalp, kanser ve diğer hastalıkların teşhis ve tedavisinde klinisyenlere yardımcı olan teşhis ve tedavi ürünleri geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden LNTH için herhangi bir risk tespit edilmedi.
LNTH Community Fair Values
Create NarrativeSee what 139 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lantheus Holdings, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$100.48 |
| 52 Haftanın En Yüksek Seviyesi | US$111.86 |
| 52 Haftanın En Düşük Seviyesi | US$49.67 |
| Beta | -0.031 |
| 1 Aylık Değişim | -3.75% |
| 3 Aylık Değişim | 6.36% |
| 1 Yıllık Değişim | 78.98% |
| 3 Yıllık Değişim | 51.44% |
| 5 Yıllık Değişim | 299.68% |
| Halka arzdan bu yana değişim | 1,462.68% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 17
LNTH: Future Returns Will Depend On Curium Deal Terms And CVR Outcomes
Analysts have modestly lifted their fair value estimate for Lantheus Holdings to about $107 per share, citing updated deal terms around Curium's proposed $102.50 cash offer, plus up to $12 in contingent value rights, and adjusted assumptions for revenue growth, profitability, discount rate, and future P/E multiples. Analyst Commentary Recent research on Lantheus Holdings has shifted sharply toward deal mechanics and return of capital, rather than ongoing fundamentals.Seeking Alpha • Aug 10
Lantheus Holdings: Why I Am Exiting Before The Merger Closes
Summary Lantheus Holdings has agreed to be acquired by Curium US Holdings for $102.50/share in cash plus a non-transferable CVR worth up to $12/share. Selling now forfeits only 1% of spread but eliminates deal-break risk. Selling now also avoids execution risk on the CVR milestones needed to collect the extra $12 by 2030. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • Aug 17
LNTH: Future Returns Will Depend On Curium Deal Terms And CVR Outcomes
Analysts have modestly lifted their fair value estimate for Lantheus Holdings to about $107 per share, citing updated deal terms around Curium's proposed $102.50 cash offer, plus up to $12 in contingent value rights, and adjusted assumptions for revenue growth, profitability, discount rate, and future P/E multiples. Analyst Commentary Recent research on Lantheus Holdings has shifted sharply toward deal mechanics and return of capital, rather than ongoing fundamentals.Seeking Alpha • Aug 10
Lantheus Holdings: Why I Am Exiting Before The Merger Closes
Summary Lantheus Holdings has agreed to be acquired by Curium US Holdings for $102.50/share in cash plus a non-transferable CVR worth up to $12/share. Selling now forfeits only 1% of spread but eliminates deal-break risk. Selling now also avoids execution risk on the CVR milestones needed to collect the extra $12 by 2030. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 03
LNTH: Takeover Talks And Alzheimer’s Prescription Trends Will Shape Future Return Potential
The analyst price target for Lantheus Holdings has shifted from $83.35 to $98.00. Analysts cite recent takeover speculation, updated assumptions for revenue growth and profit margins, and revised future P/E expectations as key factors in their revised valuation work.
Anlatı Güncellemesi • Jul 20
LNTH: Takeover Interest And Alzheimer’s Prescription Trends Will Support Future Confidence
The fair value estimate for Lantheus Holdings has been raised from $117 to $129. This reflects analysts' higher Street price targets and updated assumptions on growth, profitability, and future P/E levels.Anlatı Güncellemesi • Jul 06
LNTH: Alzheimer’s Prescription Hopes And Deal Speculation Will Limit Future Upside
The fair value estimate for Lantheus Holdings has been raised from $76.00 to about $83.35, reflecting analysts' higher price targets tied to stronger modeled revenue growth, a slightly lower discount rate, and support from recent research that points to bullish trends in Alzheimer’s prescriptions and renewed interest following a potential $7b takeout offer report. Analyst Commentary Recent Street research around Lantheus Holdings has centered on higher price targets and ongoing interest in a potential sale process, with several firms updating their models as new information on Alzheimer’s prescription trends and the reported US$7b takeout offer has surfaced.Anlatı Güncellemesi • Jun 22
LNTH: Alzheimer’s Prescription Strength And Takeover Interest Will Support Future Confidence
The analyst price target for Lantheus Holdings has moved to $115, up from $100, as analysts point to stronger Alzheimer’s prescription trends and ongoing sale discussions as key supports for the revised outlook. Analyst Commentary Recent research updates around Lantheus Holdings highlight a cluster of upbeat views as bullish analysts respond to global Alzheimer’s prescription trends and potential corporate activity reported in the market.Analiz Makalesi • Jun 16
Lantheus (LNTH) Stock And The Valuation Implications Of Its Award-Winning Imaging Agent
Lantheus Holdings (LNTH) recently drew attention after its investigational PET/CT agent LNTH-2513 (18F-GP1) received SNMMI’s Image of the Year award, backed by trial data on diagnosing acute lower-extremity deep vein thrombosis. See our latest analysis for Lantheus Holdings. The recent SNMMI recognition and upcoming Goldman Sachs healthcare conference appearance come as the stock trades at US$104.67, with a 30-day share price return of 11.46% and a year to date share price return of 55.60%,...Anlatı Güncellemesi • Jun 05
LNTH: Potential Sale And Imaging Pipeline Progress Will Support Renewed Confidence
Analysts have lifted the Lantheus Holdings fair value estimate from $114 to $117, citing higher price targets on the stock that are supported by optimism around Alzheimer’s prescription trends and updated expectations for the company’s imaging portfolio. Analyst Commentary Recent research notes on Lantheus Holdings point to a cluster of higher price targets and constructive commentary on the company’s pipeline and market opportunities.Anlatı Güncellemesi • May 20
LNTH: Future Returns Will Depend On Radiodiagnostic Execution And Royalty Pipeline Delivery
Lantheus' updated analyst price target rises from $93.92 to $104.08 as analysts factor in slightly higher revenue growth expectations, a lower discount rate and a higher assumed future P/E multiple, partly offset by more conservative profit margin assumptions. Analyst Commentary Recent research coverage on Lantheus shows a generally constructive stance, with several price target increases clustered around the latest earnings update and product commentary.Analiz Makalesi • May 14
We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings
Following the solid earnings report from Lantheus Holdings, Inc. ( NASDAQ:LNTH ), the market responded by bidding up...Anlatı Güncellemesi • May 03
LNTH: 2026 Guide And Limited Radiotherapeutic Impact Will Restrain Upside
Analysts have raised their average price target on Lantheus by a high single to low double digit dollar amount, resulting in a range that now clusters around the $80s to low $100s. They cite stronger PYLARIFY volume trends, updated assumptions for the PSMA PET opportunity, and potential medium-term contributions from royalty assets such as Flyrcado and Pylclari.Anlatı Güncellemesi • Apr 18
LNTH: Future Upside Will Rely On Radiodiagnostic Execution And Royalty Asset Contributions
The analyst price target for Lantheus Holdings has shifted modestly higher to reflect a fair value estimate of about $93.92, up from $91.38. Analysts broadly point to updated PSMA PET volume assumptions, PYLARIFY driven earnings, and potential royalty contributions from assets like Flyrcado and Pylclari as key supports for the revised outlook.Anlatı Güncellemesi • Apr 04
LNTH: Future Upside Will Depend On Execution In Radiodiagnostic Portfolio
Analysts have lifted the implied fair value for Lantheus Holdings by about $7 to roughly $91 per share, reflecting updated views on PSMA PET market volumes, the PYLARIFY TruVu rollout, and broader radiopharmaceutical product and royalty opportunities. Analyst Commentary Recent Street research on Lantheus Holdings has become more constructive overall, with several firms lifting price targets and a few voices sounding more cautious on execution and portfolio focus.Anlatı Güncellemesi • Mar 21
LNTH: Future Imaging Rollout And Radiopharmaceutical Pipeline Will Support Renewed Confidence
Analysts have modestly adjusted the Lantheus Holdings target lower to $114, reflecting slightly softer revenue growth assumptions, improved margin expectations, and updated views on PSMA PET volumes and PYLARIFY driven contributions from recent research updates. Analyst Commentary Recent Street research on Lantheus Holdings has generally leaned constructive, with several bullish analysts adjusting price targets higher and citing product execution, especially around PYLARIFY and the broader radiopharmaceutical pipeline.Anlatı Güncellemesi • Mar 06
LNTH: Fair Value Framed By 2026 Guide And Radiopharmaceutical Pipeline Execution Risks
Lantheus Holdings' updated fair value estimate has shifted from $70.00 to $76.00 as analysts factor in recent price target increases tied to PYLARIFY-driven Q4 strength and potential contributions from upcoming product and royalty opportunities. Analyst Commentary Recent research on Lantheus has been mixed, with several firms lifting price targets following a PYLARIFY driven Q4 EPS beat and stronger than expected sales, while others are tempering expectations around certain parts of the business and the timing of future revenue contributions.Anlatı Güncellemesi • Feb 19
LNTH: Future Earnings Will Rely On Execution Against Revised Risk Assumptions
Narrative Update on Lantheus Holdings The updated analyst price target for Lantheus Holdings implies a fair value shift from about $82.29 to $84.62, as analysts factor in slightly different assumptions around discount rate, revenue growth, profit margin, and future P/E following recent research that included a $5 price target reduction at TD Cowen. Analyst Commentary Recent Street research directly tied to Lantheus Holdings centers on the revised price target that trimmed the prior figure by $5, feeding into the updated fair value range around $84.62.Anlatı Güncellemesi • Feb 05
LNTH: Fair Value View Balances Higher P/E Assumptions And Execution Risks
Analysts now place their price target for Lantheus Holdings at US$70, up from US$60, reflecting updated assumptions for modestly higher revenue growth and a higher future P/E multiple, even though projected profit margins are set at a lower level. Analyst Commentary While the updated US$70 price target reflects more constructive assumptions on revenue and the future P/E multiple, not every analyst is leaning in the same direction.Analiz Makalesi • Feb 02
We Think Lantheus Holdings (NASDAQ:LNTH) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Anlatı Güncellemesi • Jan 22
LNTH: Upcoming Imaging Approvals Will Drive Confidence Despite Leadership Transition
Analysts have cut their price target for Lantheus Holdings from $128.15 to $116.06, reflecting updated assumptions for higher revenue growth and profit margins, a lower future P/E multiple, and a slightly higher discount rate. Analyst Commentary Recent Street research on utilities highlights how bullish analysts, in general, are rewarding companies that show clear growth avenues, supportive regulation, and what they view as reasonable valuation support.Anlatı Güncellemesi • Jan 08
LNTH: Execution Risks Around Guidance And Legal Overhang Will Limit Upside
Narrative Update Analysts now see fair value for Lantheus Holdings at about $60, trimming their prior $63 view as they factor in a slightly higher discount rate, modestly stronger revenue growth and margin assumptions, and a lower future P/E multiple in their refreshed models. Analyst Commentary For Lantheus Holdings, recent commentary has centered on how much upside is already reflected in the share price and how much risk investors may be taking on around future growth and profitability.Anlatı Güncellemesi • Dec 18
LNTH: Future Earnings Will Rebound As Organic Growth Visibility Strengthens
Analysts have modestly lifted their price target on Lantheus Holdings to $82.29 from $80.93, citing a slightly lower discount rate, an improved profit margin outlook, and a firmer future P/E multiple, even as revenue growth expectations moderate. Analyst Commentary Recent Street research on Lantheus reflects a more balanced stance, with the modest price target lift occurring alongside at least one high profile downgrade.Anlatı Güncellemesi • Dec 04
LNTH: Future Earnings Will Recover As Market Visibility Improves From 2027
Analysts have trimmed their price target on Lantheus Holdings, citing mounting Pylarify pricing pressures, competitive share loss risks, and higher near term operating expenses. Together, these factors temper visibility on the company’s organic growth outlook, even as the target remains clustered around the mid $70s to low $80s range.Anlatı Güncellemesi • Nov 20
LNTH: Future Earnings Will Recover As Market Visibility Improves In 2026
Analysts have lowered their price target for Lantheus Holdings from approximately $83.07 to $80.93 per share. This adjustment reflects concerns about Pylarify's pricing pressures, increased operating expenses, and uncertainties in long-term growth visibility.Anlatı Güncellemesi • Nov 06
LNTH: Future Pipeline Advances Will Drive Recovery As Market Uncertainty Fades
Lantheus Holdings' analyst price target has been reduced from $109 to a range between $63 and $84. This reflects a more cautious outlook as analysts cite continued uncertainty around Pylarify's market share and slower growth visibility in the near term.Anlatı Güncellemesi • Oct 23
Analysts Weigh In on Lantheus Holdings Amid Pylarify Challenges and Lowered Growth Forecasts
Lantheus Holdings' analyst price target was reduced slightly to $83.21 from $84.29, as analysts factor in ongoing Pylarify pricing pressures and moderated revenue growth expectations, while continued profitability helps balance these concerns. Analyst Commentary Analyst sentiment regarding Lantheus Holdings has shifted recently, with both optimistic and cautious perspectives shaping the company's investment narrative.Anlatı Güncellemesi • Oct 08
Alzheimer's And Oncology Imaging Will Create Future Opportunities
Lantheus Holdings’ analyst price target has been reduced from approximately $86.64 to $84.29, as analysts cite concerns over Pylarify’s market share, slower uptake of Alzheimer's therapeutics, and uncertainty regarding future growth drivers. Analyst Commentary Recent research reports on Lantheus Holdings indicate a shift in sentiment among analysts, with revised price targets reflecting both optimism and caution.Anlatı Güncellemesi • Sep 16
Alzheimer's And Oncology Imaging Will Create Future Opportunities
Lantheus Holdings’ consensus price target has been revised downward to $86.64, primarily due to lowered Pylarify pricing assumptions, ongoing underperformance and heightened competition, partially offset by longer-term optimism for emerging products. Analyst Commentary Lowered Pylarify pricing assumptions for 2025-2026 and increased OpEx estimates are expected to reduce near-term EPS and drive price target cuts.Analiz Makalesi • Sep 05
Positive Sentiment Still Eludes Lantheus Holdings, Inc. (NASDAQ:LNTH) Following 26% Share Price Slump
Unfortunately for some shareholders, the Lantheus Holdings, Inc. ( NASDAQ:LNTH ) share price has dived 26% in the last...Anlatı Güncellemesi • Aug 27
Alzheimer's And Oncology Imaging Will Create Future Opportunities
Analysts have trimmed Lantheus Holdings’ price target from $90.69 to $88.00, citing near-term uncertainty and deceleration in Pylarify amid competitive pressures, despite longer-term optimism for the broader pipeline. Analyst Commentary Bearish analysts cite heightened uncertainty around Pylarify's near-term prospects, with anticipated year-over-year and sequential deceleration for at least two more quarters following recent misses and guidance reductions.Anlatı Güncellemesi • Aug 07
Alzheimer's And Oncology Imaging Will Create Future Opportunities
Lantheus Holdings' valuation outlook remains stable as both the forward P/E ratio and revenue growth forecasts showed negligible changes, resulting in an unchanged analyst price target of $116.86. What's in the News Lantheus completed its $200M share repurchase program, buying back 3.43% of shares; a new $400M repurchase authorization is in place through 2027, replacing the expired prior plan.Seeking Alpha • Mar 07
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Summary Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams. Despite challenges, LNTH has potential for further growth, with promising assets in Alzheimer's and oncology, aiming for a double-digit billion market cap by decade's end. Read the full article on Seeking AlphaSeeking Alpha • Jan 02
Lantheus Holdings: Powerhouse Potential In 2025
Summary Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability. Lantheus' Alzheimer's diagnostics market investments present a significant untapped opportunity, potentially adding $1 billion in sales by 2032, enhancing the company's valuation. Read the full article on Seeking AlphaSeeking Alpha • Nov 08
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Summary Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity. Risks include patent expirations and market competition, but the company's robust pipeline provide a solid growth foundation. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Lantheus: PYLARIFY's Enhanced Prospects Are Welcome, But Don't Get Too Greedy Now
Summary On a YTD basis, Lantheus is outperforming its medical equipment peers by 3x; this wasn't the case until July, when the CMS came out with a new proposal. Even before the CMS' proposal, PYLARIFY was already seeing plenty of traction on account of the weak clinical qualities of conventional imaging tech that dominates the market. Despite positive earnings revisions to the tune of +7% for FY25, the stock is now priced at a steep forward P/E premium of 70%. Despite a robust H1 from a cash flow perspective, LNTH's free cash flow yield is below its 5-year average, and the absence of a new buyback program limits downside protection. LNTH is currently overbought and vulnerable to a pullback, with the smart money too showing some signs of cashing in. Read the full article on Seeking Alpha
Yeni Anlatı • Aug 28
PYLARIFY's Strategic Moves Foster Growth In Oncology And Alzheimer's Markets
Expansion into the Alzheimer's diagnostic space and strategic acquisitions suggest diversification and potential for long-term growth in revenue sources.Seeking Alpha • Aug 12
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
Summary PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028. Read the full article on Seeking AlphaSeeking Alpha • May 23
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
Summary Lantheus Holdings, Inc. excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging. The market for radiopharmaceuticals is expanding beyond all expectations by both industry experts and the company's management. Lantheus is actively expanding its pipeline by making strategic investments backed by a robust balance sheet. Read the full article on Seeking AlphaHissedar Getirileri
| LNTH | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -0.2% | 0.8% | -0.8% |
| 1Y | 79.0% | -11.1% | 20.5% |
Getiri vs. Endüstri: LNTH geçen yıl % -11.1 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: LNTH geçen yıl % 20.5 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| LNTH volatility | |
|---|---|
| LNTH Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: LNTH son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: LNTH 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1956 | 1,193 | Mary Heino | www.lantheus.com |
Lantheus Holdings, Inc. dünya çapında kalp, kanser ve diğer hastalıkların teşhis ve tedavisinde klinisyenlere yardımcı olan teşhis ve tedavi ürünleri geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, ekokardiyografi muayenelerinde kullanılan enjekte edilebilir bir ultrason artırıcı ajan olan DEFINITY; nükleer tıp prosedürleri için bir teknesyum jeneratörü olan TechneLite; akciğer fonksiyonunu değerlendirmek için bir radyofarmasötik gaz olan Xenon-133; inme nedeniyle kan akışının engellendiği veya azaldığı beyin içindeki alanı tanımlamak için enjekte edilebilir bir görüntüleme ajanı olan Neurolite ürünlerini sunmaktadır; Kalp kasına kan akışını değerlendirmek için enjekte edilebilir Tc-99m etiketli bir görüntüleme ajanı olan Cardiolite; ve prostat kanserli erkeklerde PSMA pozitif lezyonların görüntülenmesi için kullanılan F 18 etiketli PSMA hedefli bir PET görüntüleme ajanı olan PYLARIFY. Ayrıca, yapay sinir ağı kullanarak kemik taraması izleyici alımlarını metastatik veya iyi huylu lezyonlar olarak tespit edip sınıflandırarak prostat kanserinin hastalık yükünü hesaplayan Otomatik Kemik Tarama Endeksi; opioid kaynaklı kabızlık için RELISTOR; ve bir yapay zeka tıbbi cihaz yazılımı olan aPROMISE; prostat kanserinde PSMA PET/BT görüntülerinin nicel değerlendirmesini yapmak için bir tıbbi cihaz yazılımı olan PYLARIFY AI; ve kalbe giden kan akışını değerlendirmek için kullanılan flurpiridaz sunmaktadır.
Lantheus Holdings, Inc. Temel Bilgiler Özeti
| LNTH temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$6.54b |
| Kazançlar(TTM) | US$275.31m |
| Gelir(TTM) | US$1.56b |
23.8x
F/K Oranı4.2x
P/S OranıLNTH aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| LNTH gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.56b |
| Gelir Maliyeti | US$620.30m |
| Brüt Kâr | US$936.02m |
| Diğer Giderler | US$660.71m |
| Kazançlar | US$275.31m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 4.22 |
| Brüt Marj | 60.14% |
| Net Kâr Marjı | 17.69% |
| Borç/Özkaynak Oranı | 43.4% |
LNTH uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/19 18:07 |
| Gün Sonu Hisse Fiyatı | 2026/08/19 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Lantheus Holdings, Inc. 24 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jeffrey Johnson | Baird |
| Yuan Zhi | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |